皮肌炎患者中,主要的抗原靶点包括较大肌内膜血管的血管内皮的成分。[1]Karpati G, Hilton-Jones D, Griggs RC. Disorders of voluntary muscle. 7th ed. Cambridge, UK: Cambridge University Press; 2001.[28]Banker BQ. Dermatomyostis of childhood, ultrastructural alterations of muscle and intramuscular blood vessels. J Neuropathol Exp Neurol. 1975;34:46-75.http://www.ncbi.nlm.nih.gov/pubmed/1117321?tool=bestpractice.com[29]Carpenter S, Karpati G, Rothman S, et al. The childhood type of dermatomyositis. Neurology. 1976;26:952-962.http://www.ncbi.nlm.nih.gov/pubmed/183170?tool=bestpractice.com补体活化导致补体溶膜攻击复合物沉淀在肌内膜微脉管系统上。这导致毛细管坏死、微梗塞、炎症、内束灌注不足并最终导致束周萎缩。[30]Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567.http://www.ncbi.nlm.nih.gov/pubmed/15367860?tool=bestpractice.com[31]Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325:1487-1498.http://www.ncbi.nlm.nih.gov/pubmed/1658649?tool=bestpractice.com这在毛细管网密度较低的肌束周围最突出。[30]Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567.http://www.ncbi.nlm.nih.gov/pubmed/15367860?tool=bestpractice.com淋巴细胞浸润受感染肌肉的肌束膜和血管周区域,支持皮肌炎发病机制中的体液介导型过程。[30]Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567.http://www.ncbi.nlm.nih.gov/pubmed/15367860?tool=bestpractice.com
在多发性肌炎和包涵体肌炎中,有证据表明抗原指导的和主要组织相容性复合体-1 (MHC-1) 限制性细胞毒性由 CD8 T 细胞进行调节。[30]Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567.http://www.ncbi.nlm.nih.gov/pubmed/15367860?tool=bestpractice.com多发性肌炎患者中,CD8 T 与 MHC-1 间的免疫突触表达于肌纤维上。[30]Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567.http://www.ncbi.nlm.nih.gov/pubmed/15367860?tool=bestpractice.com多发性肌炎与包涵体肌炎患者中,表达于肌纤维上的可诱导性辅助刺激因子 (ICOS) 配体与自身侵袭性 T 细胞上的 ICOS 受体相互作用。这有助于记忆 T 细胞进行克隆性扩增和共刺激。[30]Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567.http://www.ncbi.nlm.nih.gov/pubmed/15367860?tool=bestpractice.com介导抑制 T 细胞活化的程序性死亡配体也表达于肌纤维中。[30]Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567.http://www.ncbi.nlm.nih.gov/pubmed/15367860?tool=bestpractice.com这些症状说明:
细胞因子、趋化因子及粘附分子有助于激活的 T 细胞粘连肌纤维。[30]Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol. 2004;17:561-567.http://www.ncbi.nlm.nih.gov/pubmed/15367860?tool=bestpractice.com[31]Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325:1487-1498.http://www.ncbi.nlm.nih.gov/pubmed/1658649?tool=bestpractice.com[32]Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology. 2000;54:65-71.http://www.ncbi.nlm.nih.gov/pubmed/10636127?tool=bestpractice.com[33]Lindvall B, Dahlbom K, Henriksson KG, et al. The expression of adhesion molecules in muscle biopsies: the LFA-1/VLA-4 ratio in polymyositis. Acta Neurol Scand. 2003;107:134-141.http://www.ncbi.nlm.nih.gov/pubmed/12580864?tool=bestpractice.com
皮肌炎的另一个发病机理表明,一个或多个干扰素 1 诱导蛋白在细胞内慢性生产过剩会损伤内皮细胞与肌纤维。这是基于对组织病理学与干扰素 1 相关病理学的观察得出的结论。浆细胞样树突状细胞在肌束膜区域通常呈典型的浆细胞样形态(制造干扰素 1 的活化型)。这导致肌内膜束周区内干扰素 1 的浓度较高,并且经过某些未确认的机制,可能会促进束周萎缩。[34]Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007;69:2008-2019.http://www.ncbi.nlm.nih.gov/pubmed/17928577?tool=bestpractice.com[35]Greenberg SA. Inflammatory myopathies: disease mechanisms. Curr Opin Neurol. 2009;22:516-523.http://www.ncbi.nlm.nih.gov/pubmed/19680126?tool=bestpractice.com[36]Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep. 2010;12:198-203.http://www.ncbi.nlm.nih.gov/pubmed/20425524?tool=bestpractice.com